• Explore /
  • Poster
  • / A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).

A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).

Abstract Poster

Authors

null

Kunle Odunsi

Roswell Park Cancer Institute, Buffalo, NY

Kunle Odunsi , Mihaela C. Cristea , Oliver Dorigo , Amir A. Jazaeri , Brian M. Slomovitz , Karen Chagin , Erin Van Winkle , Gabor Kari , Malini Iyengar , Elliot Norry , Arundathy N. Bartlett-Pandite , Rafael G. Amado

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research,Immunotherapy

Sub Track

Cellular Immunotherapy

Clinical Trial Registration Number

NCT01567891

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS3094)

DOI

10.1200/JCO.2017.35.15_suppl.TPS3094

Abstract #

TPS3094

Poster Bd #

187b

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Annual Meeting

<span>Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.</span>

Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.

First Author: Jiayong Liu

First Author: Sandra P. D'Angelo

First Author: Marcus O. Butler

First Author: Dejka M. Araujo